Venetoclax Adds a New Arrow Targeting Relapsed CLL to the Quiver

Kerry A Rogers; John C Byrd

doi:10.1016/j.ccell.2015.12.010

Venetoclax Adds a New Arrow Targeting Relapsed CLL to the Quiver

Cancer Cell. 2016 Jan 11;29(1):3-4. doi: 10.1016/j.ccell.2015.12.010.

Authors

Kerry A Rogers¹, John C Byrd²

Affiliations

¹ Division of Hematology, The Ohio State University, Columbus, OH 43210, USA.
² Division of Hematology, The Ohio State University, Columbus, OH 43210, USA. Electronic address: [email protected].

PMID: 26766586
DOI: 10.1016/j.ccell.2015.12.010

Abstract

Inhibitors of B cell receptor signaling substantially changed the treatment of chronic lymphocytic leukemia as the first targeted agents to enter routine clinical practice. A recent paper by Roberts and colleagues describes an additional therapeutic target by reporting encouraging clinical results with venetoclax, an inhibitor of the antiapoptotic protein BCL2.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Aniline Compounds / administration & dosage*
Aniline Compounds / pharmacology*
Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / pharmacology*
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Male
Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors*
Proto-Oncogene Proteins c-bcl-2 / metabolism*
Sulfonamides / administration & dosage*
Sulfonamides / pharmacology*

Substances

Aniline Compounds
Antineoplastic Agents
Proto-Oncogene Proteins c-bcl-2
Sulfonamides

Abstract

Publication types

MeSH terms

Substances

Grants and funding